Developer docs
API playgroundTry for free, no card

Search company profiles

Centre for Probe Development and Commercialization

Full company profile

uuid0002uv7

Namestring
Centre for Probe Development and Commercialization
Legal namestring
Centre for Probe Development and Commercialization
Websiteurl
cpdc.ca
Company typeenum
Private
Founded yearint
2008
Descriptiontext

CPDC is a Canadian not-for-profit organization founded in 2008 by Dr. John Valliant of McMaster University, headquartered in Hamilton, Ontario, that advances nuclear medicine and radiopharmaceutical development for both Canadian and global patients. Its core activities span the full radiopharmaceutical lifecycle: preclinical research and development (Cadena Research, launched September 2025 as a wholly-owned CRO), GMP-compliant manufacturing and advisory services, clinical trial support (60+ trials conducted across North America and Europe over 15 years), and the delivery of more than 65,000 clinical doses to Canadian patients. The organization also holds exclusive Canadian licensing rights for PSMA-1007, a Phase III-completed 18F-labeled diagnostic imaging agent for prostate cancer expected to reach Canadian patients in 2026.

CPDC's business model combines multiple revenue streams rather than a single pricing structure. Professional services revenue is generated through Cadena Research (preclinical CRO services) and GMP advisory work. Licensing royalties flow from in-licensed assets like PSMA-1007 (from ABX GmbH). Strategic investment activity generates returns through seed and Series A investments in radiopharmaceutical startups, exemplified by the $650,000 seed investment in RadioSyn (June 2025). The company creation/spin-out model — responsible for founding or incubating Fusion Pharmaceuticals, AtomVie Global Radiopharma, ARTMS, and CanProbe — provides both reputational returns and potential future exit upside. Major government backing through the co-led $80M Canadian Medical Isotope Ecosystem (CMIE) initiative and prior $8M Government of Canada grant provides non-dilutive funding for ecosystem programs.

The organization serves a diverse customer base including early-stage radiopharmaceutical startups, academic researchers, biotechnology companies, large pharmaceutical firms, and government/healthcare entities. Its go-to-market combines direct enterprise outreach (via partnering@cpdc.ca), industry events (such as the CMIE-CNIC Symposium on Medical Isotopes), and ecosystem-led community engagement through CMIE. With 51-100 employees and recent senior leadership expansion across business development, quality operations, contract research, and CMIE ecosystem functions, CPDC operates as a sector orchestrator for Canadian radiopharmaceutical development rather than a traditional commercial entity.

Short descriptiontext

CPDC is a Canadian not-for-profit advancing nuclear medicine through radiopharmaceutical development, GMP manufacturing, preclinical CRO services (Cadena Research), strategic investments, and spin-out company creation. It serves radiopharmaceutical innovators, academic researchers, and biotech and pharmaceutical companies in Canada and globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHamilton, Canada
HQ citystring
Hamilton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical development, preclinical contract research, GMP manufacturing services, nuclear medicine development, radiopharmaceutical licensing
Industry5 codes
PRIMARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Radiopharmaceutical Development Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Strategic Investments
TypeLicensing Royalties
Description

CPDC makes direct Seed and Series A investments in early-stage radiopharmaceutical companies and technologies, seeking to enhance value and advance impact of innovations in the sector.

cpdc.ca
2GMP Advisory Services
TypeProfessional Services
Description

Specialized quality and GMP advisory services tailored to the unique needs of the Canadian radiopharmaceutical industry, offering end-to-end guidance for compliance across manufacturing and control processes.

cpdc.ca
3Contract Research Services (Cadena Research)
TypeProfessional Services
Description

Preclinical contract research organization providing laboratory services for radiopharmaceutical development from early-stage research through IND-enabling studies, including advisory services covering all drug development stages.

cpdc.ca
4Licensing and Commercialization
TypeLicensing Royalties
Description

CPDC holds exclusive licensing rights for PSMA-1007 from ABX GmbH to manufacture, commercialize and distribute imaging agents in Canada, with plans to bring diagnostic tools to the Canadian market.

cpdc.ca
5Company Creation and Spin-outs
TypeLicensing Royalties
Description

CPDC incubates and spins out companies from its research, having successfully created Fusion Pharmaceuticals, AtomVie Global Radiopharma, ARTMS, and CanProbe, creating commercial entities that advance radiopharmaceutical availability.

cpdc.ca
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Cadena Research
Description

A preclinical contract research organization (CRO) created by CPDC to accelerate the development of radiopharmaceuticals. Provides comprehensive preclinical development support including in vitro and in vivo R&D, screening, lead optimization, toxicology, dosimetry, imaging, and advanced radiochemistry capabilities.

cpdc.ca
Core offering1 text field

CPDC develops, manufactures, and commercialises radiopharmaceuticals and molecular imaging probes through a preclinical CRO (Cadena Research), GMP advisory services, and exclusive licensing of diagnostic agents such as PSMA-1007. It also provides strategic investments, in-licensing, and company-creation services to accelerate radiopharmaceutical innovation. The organisation co-leads the $80M Canadian Medical Isotope Ecosystem (CMIE) to advance the broader medical isotope sector.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 60 clinical trials supported and conducted in Canada, North America, and Europe
+3 more records
Product overview1 text field

CPDC is a not-for-profit organization advancing nuclear medicine through radiopharmaceutical development. The portfolio consists of a core contract research organization (Cadena Research) offering preclinical development services, a Phase III-stage diagnostic agent (PSMA-1007) for prostate cancer, GMP advisory services, and the Canadian Medical Isotope Ecosystem (CMIE) initiative. CPDC has also successfully created spin-out companies including Fusion Pharmaceuticals (acquired by AstraZeneca), AtomVie Global Radiopharma (CDMO), and ARTMS (acquired by Telix Pharmaceuticals).

Product and service4 records
1Cadena Research
CategoryPreclinical Contract Research
Description

A preclinical Contract Research Organization (CRO) offering comprehensive development support for radiopharmaceutical innovators worldwide. Services include in vitro and in vivo R&D, screening, lead optimization, toxicology, dosimetry, imaging, and advanced radiochemistry capabilities, plus GLP capabilities for IND-enabling studies. Targeted at startups, academic innovators, biotechnology companies, and large pharmaceutical firms developing radiopharmaceuticals.

2PSMA-1007
CategoryDiagnostic Imaging Agent
Description

An 18F-labeled diagnostic imaging agent targeting prostate specific membrane antigen (PSMA) protein for prostate cancer detection. CPDC holds exclusive licensing rights from ABX GmbH (Germany) to manufacture, commercialise, and distribute the imaging agent in Canada. Completed Phase III clinical trials and expected to be available to Canadian patients in 2026.

3GMP Services
CategoryGMP Quality and Regulatory Advisory
Description

Specialised quality and GMP advisory services tailored to the Canadian radiopharmaceutical industry, with over 15 years of experience in clinical and commercial applications. Offers end-to-end guidance for GMP assessments, audit readiness, and ongoing quality assurance operations with systems that have consistently met the highest standards during regulatory inspections and client audits.

4Canadian Medical Isotope Ecosystem (CMIE)
CategoryEcosystem Program / Grant Funding
Description

An $80M initiative co-led by CPDC and TRIUMF Innovations, backed by Government of Canada's Strategic Innovation Fund, uniting stakeholders in the medical isotope sector to accelerate technology development and commercialisation. Includes a $5M development fund (CMIEDF) offering financial support to innovators, developers, and academic institutions across Canada.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

CQDM and CPDC launched a strategic initiative to support next-generation radiopharmaceutical development in Canada, with a call for ideas open to innovative companies and researchers. Selected participants may receive direct investments or collaboration opportunities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership to launch L2M Discover Radiopharma program, a 10-week virtual training program to cultivate entrepreneurial skills among Canadian researchers in the radiopharmaceutical sector, beginning September 2025.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

CNIC partnered with CMIE to host the 1st Annual Symposium on Medical Isotopes, bringing together industry leaders, researchers, and innovators to advance Canada's medical isotope sector.

Strategic tierCoreTypeOthersAnnounced on2022-01-01
Description

Spun out of CPDC in 2022, AtomVie is a global leading CDMO for radiotherapeutics, leveraging 10 years of expertise in GMP manufacturing and global distribution of radiopharmaceuticals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

CPDC and TRIUMF Innovations joined forces in 2020 to co-lead the Canadian Medical Isotope Ecosystem (CMIE), an $80M initiative backed by the Government of Canada's Strategic Innovation Fund. TRIUMF Innovations bridges Canada's national particle accelerator laboratory with the business world.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

In 2016, Dana-Farber and CPDC joined to create the International Probe Development Consortium (IPDC), combining expertise in radiopharmaceutical development and cancer research to create novel molecular probes for non-invasive imaging in cancer research, drug development, and patient care.

Strategic tierCoreTypeOthersAnnounced on2016-01-01
Description

Spun out of CPDC in 2016, Fusion Pharmaceuticals developed next-generation radiopharmaceuticals as precision medicines for cancer treatment. Acquired by AstraZeneca in 2024 for up to $2.4B USD.

Strategic tierCoreTypeOthersAnnounced on2013-01-01
Description

Founded in 2013 by CPDC, TRIUMF, Lawson Health Research Institute, and BC Cancer. Specializes in cyclotron-produced radionuclides with its QUANTM Irradiation System (QIS). Acquired by Telix Pharmaceuticals in 2024 for up to $82M USD.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2008-01-01
Description

McMaster University provided supporting infrastructure to CPDC from its launch in 2008 until 2022. McMaster has a long history in Nuclear Research spanning more than 50 years since the opening of the McMaster Nuclear Reactor (MNR) in 1959, recognized as a world-leader in radiation sciences, nuclear engineering, medical isotope and radiopharmaceutical production.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

OICR has enabled funding of early-stage discovery projects at various academic institutions in Canada, provided regulatory support for clinical trials in Ontario, and helped bring new cancer diagnostic agents to Canadians. OICR is an innovative cancer research and development institute funded by the Government of Ontario, supporting more than 1,700 investigators.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lawson and CPDC have a long-standing relationship as co-founders of ARTMS, along with TRIUMF and BC Cancer Agency. Lawson has partnered with CPDC as a manufacturing and clinical site for CPDC's Phase 3 clinical trial for [18F]PSMA-1007, a diagnostic agent for prostate cancer.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

The DHDP is a pan-Canadian initiative bringing together health researchers, AI experts, and industry partners to accelerate precision medicine. CPDC will collaborate with national partners to advance AI-enabled, data-driven analysis in oncology and other disease areas.

Strategic tierMinorTypeOthers
Description

think-cell is a charting and layout software used for creating charts in Microsoft PowerPoint presentations.

14CanProbe
Strategic tierMinorTypeOthers
Description

Co-founded by CPDC as part of its role in advancing the Canadian radiopharmaceutical ecosystem.

cpdc.ca
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spun out from CPDC in 2022, AtomVie is a global CDMO for radiotherapeutics built on CPDC's GMP platform, offering Phase 1 to commercial manufacturing and distribution. It is the most directly comparable peer given shared DNA and overlapping services.

TypeDirect peer
Description

One of the largest global radiopharmaceutical CDMOs, supplying SPECT/PET diagnostic and therapeutic products worldwide. Closely comparable to CPDC's GMP manufacturing and CDMO activities via AtomVie.

TypeDirect peer
Description

Operates the largest network of PET radiopharma manufacturing centers globally under Siemens Healthineers, providing GMP PET tracer production. Directly comparable to CPDC's GMP and radiotracer capabilities.

TypeBroad incumbent
Description

Established radiopharmaceutical company with diagnostic imaging agents (e.g., Pylarify PSMA, DEFINITY) and growing radiotherapeutic pipeline. Overlaps with CPDC on PSMA-1007 competitive landscape and broader CDMO/CDN footprint.

TypeDirect peer
Description

Commercial-stage radiopharma company that acquired ARTMS (a CPDC spin-out) in 2024 for up to $82M USD; develops and commercializes diagnostic and therapeutic radiopharmaceuticals globally. Direct competitor and former portfolio company.

TypeBroad incumbent
Description

Major pharma with a radioligand therapy franchise (Xofigo heritage from Algeta) and pipeline of targeted radiotherapeutics. Comparable as a large incumbent active in radiopharmaceutical commercialization and manufacturing.

TypeBroad incumbent
Description

Operates a global radiopharmaceutical manufacturing and distribution network and supplies molecular imaging agents. Comparable as a broad incumbent in radiopharma manufacturing and commercialization adjacent to CPDC's GMP CDMO model.

TypeDirect peer
Description

Vertically integrated radiopharmaceutical company producing medical radioisotopes and developing targeted radiotherapeutics with in-house CDMO capabilities. Comparable to CPDC across isotope supply, GMP, and therapeutic development.

TypeBroad incumbent
Description

Operates one of the largest U.S. radiopharma distribution and manufacturing networks for radiopharmaceuticals. Comparable as an established distributor/manufacturer serving similar nuclear medicine end-customers.

TypeOthers
Description

Spun out from CPDC in 2016 and acquired by AstraZeneca in 2024 for up to $2.4B USD; develops targeted alpha therapies. Included as a former portfolio company and ecosystem alumnus rather than a current direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Centre for Probe Development and Commercialization

Radiopharmaceutical Development Servicescpdc.ca

CPDC is a Canadian not-for-profit advancing nuclear medicine through radiopharmaceutical development, GMP manufacturing, preclinical CRO services (Cadena Research), strategic investments, and spin-out company creation. It serves radiopharmaceutical innovators, academic researchers, and biotech and pharmaceutical companies in Canada and globally.

What Centre for Probe Development and Commercialization does

CPDC is a Canadian not-for-profit organization founded in 2008 by Dr. John Valliant of McMaster University, headquartered in Hamilton, Ontario, that advances nuclear medicine and radiopharmaceutical development for both Canadian and global patients. Its core activities span the full radiopharmaceutical lifecycle: preclinical research and development (Cadena Research, launched September 2025 as a wholly-owned CRO), GMP-compliant manufacturing and advisory services, clinical trial support (60+ trials conducted across North America and Europe over 15 years), and the delivery of more than 65,000 clinical doses to Canadian patients. The organization also holds exclusive Canadian licensing rights for PSMA-1007, a Phase III-completed 18F-labeled diagnostic imaging agent for prostate cancer expected to reach Canadian patients in 2026.

CPDC's business model combines multiple revenue streams rather than a single pricing structure. Professional services revenue is generated through Cadena Research (preclinical CRO services) and GMP advisory work. Licensing royalties flow from in-licensed assets like PSMA-1007 (from ABX GmbH). Strategic investment activity generates returns through seed and Series A investments in radiopharmaceutical startups, exemplified by the $650,000 seed investment in RadioSyn (June 2025). The company creation/spin-out model — responsible for founding or incubating Fusion Pharmaceuticals, AtomVie Global Radiopharma, ARTMS, and CanProbe — provides both reputational returns and potential future exit upside. Major government backing through the co-led $80M Canadian Medical Isotope Ecosystem (CMIE) initiative and prior $8M Government of Canada grant provides non-dilutive funding for ecosystem programs.

The organization serves a diverse customer base including early-stage radiopharmaceutical startups, academic researchers, biotechnology companies, large pharmaceutical firms, and government/healthcare entities. Its go-to-market combines direct enterprise outreach (via partnering@cpdc.ca), industry events (such as the CMIE-CNIC Symposium on Medical Isotopes), and ecosystem-led community engagement through CMIE. With 51-100 employees and recent senior leadership expansion across business development, quality operations, contract research, and CMIE ecosystem functions, CPDC operates as a sector orchestrator for Canadian radiopharmaceutical development rather than a traditional commercial entity.

Centre for Probe Development and Commercialization firmographics

Firmographics
Name
Centre for Probe Development and Commercialization
Legal name
Centre for Probe Development and Commercialization
Website
https://cpdc.ca
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
CPDC is a Canadian not-for-profit advancing nuclear medicine through radiopharmaceutical development, GMP manufacturing, preclinical CRO services (Cadena Research), strategic investments, and spin-out company creation. It serves radiopharmaceutical innovators, academic researchers, and biotech and pharmaceutical companies in Canada and globally.
Ownership category
akta.pro rank

Centre for Probe Development and Commercialization industry classification

Industry
Product category
Radiopharmaceutical Development Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Radiopharmaceutical development
  • Preclinical contract research
  • GMP manufacturing services
  • Nuclear medicine development
  • Radiopharmaceutical licensing

Where Centre for Probe Development and Commercialization is headquartered

Location

Headquarters

HQ city
Hamilton
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Centre for Probe Development and Commercialization business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Investments: CPDC makes direct Seed and Series A investments in early-stage radiopharmaceutical companies and technologies, seeking to enhance value and advance impact of innovations in the sector.
  2. GMP Advisory Services: Specialized quality and GMP advisory services tailored to the unique needs of the Canadian radiopharmaceutical industry, offering end-to-end guidance for compliance across manufacturing and control processes.
  3. Contract Research Services (Cadena Research): Preclinical contract research organization providing laboratory services for radiopharmaceutical development from early-stage research through IND-enabling studies, including advisory services covering all drug development stages.
  4. Licensing and Commercialization: CPDC holds exclusive licensing rights for PSMA-1007 from ABX GmbH to manufacture, commercialize and distribute imaging agents in Canada, with plans to bring diagnostic tools to the Canadian market.
  5. Company Creation and Spin-outs: CPDC incubates and spins out companies from its research, having successfully created Fusion Pharmaceuticals, AtomVie Global Radiopharma, ARTMS, and CanProbe, creating commercial entities that advance radiopharmaceutical availability.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Centre for Probe Development and Commercialization product offering

Product offering

Core offering

CPDC develops, manufactures, and commercialises radiopharmaceuticals and molecular imaging probes through a preclinical CRO (Cadena Research), GMP advisory services, and exclusive licensing of diagnostic agents such as PSMA-1007. It also provides strategic investments, in-licensing, and company-creation services to accelerate radiopharmaceutical innovation. The organisation co-leads the $80M Canadian Medical Isotope Ecosystem (CMIE) to advance the broader medical isotope sector.

Product overview

CPDC is a not-for-profit organization advancing nuclear medicine through radiopharmaceutical development. The portfolio consists of a core contract research organization (Cadena Research) offering preclinical development services, a Phase III-stage diagnostic agent (PSMA-1007) for prostate cancer, GMP advisory services, and the Canadian Medical Isotope Ecosystem (CMIE) initiative. CPDC has also successfully created spin-out companies including Fusion Pharmaceuticals (acquired by AstraZeneca), AtomVie Global Radiopharma (CDMO), and ARTMS (acquired by Telix Pharmaceuticals).

Differentiator

Problem solved

Functional benefit

Brands

  • Cadena Research: A preclinical contract research organization (CRO) created by CPDC to accelerate the development of radiopharmaceuticals. Provides comprehensive preclinical development support including in vitro and in vivo R&D, screening, lead optimization, toxicology, dosimetry, imaging, and advanced radiochemistry capabilities.

Products and services

  • Cadena Research A preclinical Contract Research Organization (CRO) offering comprehensive development support for radiopharmaceutical innovators worldwide. Services include in vitro and in vivo R&D, screening, lead optimization, toxicology, dosimetry, imaging, and advanced radiochemistry capabilities, plus GLP capabilities for IND-enabling studies. Targeted at startups, academic innovators, biotechnology companies, and large pharmaceutical firms developing radiopharmaceuticals.
  • PSMA-1007 An 18F-labeled diagnostic imaging agent targeting prostate specific membrane antigen (PSMA) protein for prostate cancer detection. CPDC holds exclusive licensing rights from ABX GmbH (Germany) to manufacture, commercialise, and distribute the imaging agent in Canada. Completed Phase III clinical trials and expected to be available to Canadian patients in 2026.
  • GMP Services Specialised quality and GMP advisory services tailored to the Canadian radiopharmaceutical industry, with over 15 years of experience in clinical and commercial applications. Offers end-to-end guidance for GMP assessments, audit readiness, and ongoing quality assurance operations with systems that have consistently met the highest standards during regulatory inspections and client audits.
  • Canadian Medical Isotope Ecosystem (CMIE) An $80M initiative co-led by CPDC and TRIUMF Innovations, backed by Government of Canada's Strategic Innovation Fund, uniting stakeholders in the medical isotope sector to accelerate technology development and commercialisation. Includes a $5M development fund (CMIEDF) offering financial support to innovators, developers, and academic institutions across Canada.

Quantifiable outcome

  • Over 60 clinical trials supported and conducted in Canada, North America, and Europe
  • +3 more outcomes

Companies that use Centre for Probe Development and Commercialization

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Centre for Probe Development and Commercialization technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Centre for Probe Development and Commercialization partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered minor and core.

  • CQDMminorStrategic or Co-development Partner · 1 January 2025CQDM and CPDC launched a strategic initiative to support next-generation radiopharmaceutical development in Canada, with a call for ideas open to innovative companies and researchers. Selected participants may receive direct investments or collaboration opportunities.
  • Lab2Market (L2M)minorStrategic or Co-development Partner · 1 January 2025Partnership to launch L2M Discover Radiopharma program, a 10-week virtual training program to cultivate entrepreneurial skills among Canadian researchers in the radiopharmaceutical sector, beginning September 2025.
  • Canadian Nuclear Isotope Council (CNIC)minorStrategic or Co-development Partner · 1 January 2024CNIC partnered with CMIE to host the 1st Annual Symposium on Medical Isotopes, bringing together industry leaders, researchers, and innovators to advance Canada's medical isotope sector.
  • AtomVie Global Radiopharma Inc.coreOthers · 1 January 2022Spun out of CPDC in 2022, AtomVie is a global leading CDMO for radiotherapeutics, leveraging 10 years of expertise in GMP manufacturing and global distribution of radiopharmaceuticals.
  • TRIUMF InnovationscoreStrategic or Co-development Partner · 1 January 2020CPDC and TRIUMF Innovations joined forces in 2020 to co-lead the Canadian Medical Isotope Ecosystem (CMIE), an $80M initiative backed by the Government of Canada's Strategic Innovation Fund. TRIUMF Innovations bridges Canada's national particle accelerator laboratory with the business world.
  • Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 1 January 2016In 2016, Dana-Farber and CPDC joined to create the International Probe Development Consortium (IPDC), combining expertise in radiopharmaceutical development and cancer research to create novel molecular probes for non-invasive imaging in cancer research, drug development, and patient care.
  • Fusion Pharmaceuticals Inc.coreOthers · 1 January 2016Spun out of CPDC in 2016, Fusion Pharmaceuticals developed next-generation radiopharmaceuticals as precision medicines for cancer treatment. Acquired by AstraZeneca in 2024 for up to $2.4B USD.
  • ARTMScoreOthers · 1 January 2013Founded in 2013 by CPDC, TRIUMF, Lawson Health Research Institute, and BC Cancer. Specializes in cyclotron-produced radionuclides with its QUANTM Irradiation System (QIS). Acquired by Telix Pharmaceuticals in 2024 for up to $82M USD.
  • McMaster UniversitycoreStrategic or Co-development Partner · 1 January 2008McMaster University provided supporting infrastructure to CPDC from its launch in 2008 until 2022. McMaster has a long history in Nuclear Research spanning more than 50 years since the opening of the McMaster Nuclear Reactor (MNR) in 1959, recognized as a world-leader in radiation sciences, nuclear engineering, medical isotope and radiopharmaceutical production.
  • Ontario Institute for Cancer Research (OICR)coreStrategic or Co-development PartnerOICR has enabled funding of early-stage discovery projects at various academic institutions in Canada, provided regulatory support for clinical trials in Ontario, and helped bring new cancer diagnostic agents to Canadians. OICR is an innovative cancer research and development institute funded by the Government of Ontario, supporting more than 1,700 investigators.
  • Lawson Health Research InstitutecoreStrategic or Co-development PartnerLawson and CPDC have a long-standing relationship as co-founders of ARTMS, along with TRIUMF and BC Cancer Agency. Lawson has partnered with CPDC as a manufacturing and clinical site for CPDC's Phase 3 clinical trial for [18F]PSMA-1007, a diagnostic agent for prostate cancer.
  • Digital Health Discovery Platform (DHDP)minorStrategic or Co-development PartnerThe DHDP is a pan-Canadian initiative bringing together health researchers, AI experts, and industry partners to accelerate precision medicine. CPDC will collaborate with national partners to advance AI-enabled, data-driven analysis in oncology and other disease areas.
  • think-cellminorOthersthink-cell is a charting and layout software used for creating charts in Microsoft PowerPoint presentations.
  • CanProbeminorOthersCo-founded by CPDC as part of its role in advancing the Canadian radiopharmaceutical ecosystem.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Centre for Probe Development and Commercialization competitors and assessment

Company assessment

Direct peers

  • AtomVie Global Radiopharma: Spun out from CPDC in 2022, AtomVie is a global CDMO for radiotherapeutics built on CPDC's GMP platform, offering Phase 1 to commercial manufacturing and distribution. It is the most directly comparable peer given shared DNA and overlapping services.
  • Curium Pharma: One of the largest global radiopharmaceutical CDMOs, supplying SPECT/PET diagnostic and therapeutic products worldwide. Closely comparable to CPDC's GMP manufacturing and CDMO activities via AtomVie.
  • PETNET Solutions (Siemens Healthineers): Operates the largest network of PET radiopharma manufacturing centers globally under Siemens Healthineers, providing GMP PET tracer production. Directly comparable to CPDC's GMP and radiotracer capabilities.
  • Telix Pharmaceuticals: Commercial-stage radiopharma company that acquired ARTMS (a CPDC spin-out) in 2024 for up to $82M USD; develops and commercializes diagnostic and therapeutic radiopharmaceuticals globally. Direct competitor and former portfolio company.
  • ITM Isotope Technologies Munich: Vertically integrated radiopharmaceutical company producing medical radioisotopes and developing targeted radiotherapeutics with in-house CDMO capabilities. Comparable to CPDC across isotope supply, GMP, and therapeutic development.

Broad incumbents

  • Lantheus Holdings: Established radiopharmaceutical company with diagnostic imaging agents (e.g., Pylarify PSMA, DEFINITY) and growing radiotherapeutic pipeline. Overlaps with CPDC on PSMA-1007 competitive landscape and broader CDMO/CDN footprint.
  • Bayer (Radiopharmaceuticals / Algeta heritage): Major pharma with a radioligand therapy franchise (Xofigo heritage from Algeta) and pipeline of targeted radiotherapeutics. Comparable as a large incumbent active in radiopharmaceutical commercialization and manufacturing.
  • GE HealthCare: Operates a global radiopharmaceutical manufacturing and distribution network and supplies molecular imaging agents. Comparable as a broad incumbent in radiopharma manufacturing and commercialization adjacent to CPDC's GMP CDMO model.
  • Cardinal Health Nuclear & Pharmacy Services: Operates one of the largest U.S. radiopharma distribution and manufacturing networks for radiopharmaceuticals. Comparable as an established distributor/manufacturer serving similar nuclear medicine end-customers.

Others

  • Fusion Pharmaceuticals (AstraZeneca): Spun out from CPDC in 2016 and acquired by AstraZeneca in 2024 for up to $2.4B USD; develops targeted alpha therapies. Included as a former portfolio company and ecosystem alumnus rather than a current direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

Centre for Probe Development and Commercialization social profiles

Digital presence

Centre for Probe Development and Commercialization financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Centre for Probe Development and Commercialization leadership team

Management profile

Number of profiles

Profiles8 records

Centre for Probe Development and Commercialization subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Centre for Probe Development and Commercialization funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Centre for Probe Development and Commercialization M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre for Probe Development and Commercialization

What does Centre for Probe Development and Commercialization do?

CPDC develops, manufactures, and commercialises radiopharmaceuticals and molecular imaging probes through a preclinical CRO (Cadena Research), GMP advisory services, and exclusive licensing of diagnostic agents such as PSMA-1007. It also provides strategic investments, in-licensing, and company-creation services to accelerate radiopharmaceutical innovation. The organisation co-leads the $80M Canadian Medical Isotope Ecosystem (CMIE) to advance the broader medical isotope sector.

Is Centre for Probe Development and Commercialization a public or private company?

Centre for Probe Development and Commercialization is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Centre for Probe Development and Commercialization founded?

Centre for Probe Development and Commercialization was founded in 2008. It employs 11 to 50 people.

Where is Centre for Probe Development and Commercialization based?

Centre for Probe Development and Commercialization is headquartered in Hamilton, Canada, in the North America region.

How does Centre for Probe Development and Commercialization make money?

Five revenue lines are on record. Strategic Investments are the primary driver. The others are GMP Advisory Services, contract Research Services (Cadena Research), licensing and Commercialization and company Creation and Spin-outs.

Who are Centre for Probe Development and Commercialization's main competitors?

Direct peers on record are AtomVie Global Radiopharma, Curium Pharma, PETNET Solutions (Siemens Healthineers), Telix Pharmaceuticals and ITM Isotope Technologies Munich. Broad incumbents are Lantheus Holdings, Bayer (Radiopharmaceuticals / Algeta heritage), GE HealthCare and Cardinal Health Nuclear & Pharmacy Services. Fusion Pharmaceuticals (AstraZeneca) is listed as an others.

Does Centre for Probe Development and Commercialization have an API?

No public API is recorded for Centre for Probe Development and Commercialization.

What industry is Centre for Probe Development and Commercialization in?

Centre for Probe Development and Commercialization's product category is Radiopharmaceutical Development Services. Its primary akta.pro industry code is EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC), with a secondary code of HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCPDC Launches Cadena Research, a Radiopharmaceutical Preclinical CROCPDC launched Cadena Research, a preclinical CRO for radiopharmaceuticals, offering in vitro/in vivo research, toxicology, dosimetry, and GLP IND-enabling studies. The organization is led by Martin Poirier and aims to accelerate early-stage drug development for clients worldwide.PR NewswireAtomVie Global Radiopharma Inc. presents at key investor conferencesAtomVie Global Radiopharma Inc. announced it has been selected to present at two upcoming investor conferences: the Jefferies Radiopharma Innovation Summit in New York on April 3rd, 2023, and the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 25th, 2023. The company, officially launched in August 2022 with a $40 million Series A financing, is a radiopharmaceutical contract development and manufacturing organization spinout from the Centre for Probe Development and Commercialization at McMaster University. AtomVie currently serves 10 international clients conducting studies in over 17 countries worldwide.PR NewswireDas Centre for Probe Development and Commercialization expandiert nach Asien und schließt mit dem südkoreanischen Unternehmen CellBion einen Vertrag über die Entwicklung, Herstellung und klinische LieDas Centre for Probe Development and Commercialization hat mit dem südkoreanischen Unternehmen CellBion einen Vertrag über die Entwicklung, Herstellung und klinische Lieferung von 177Lu-PSMA (DGUL) abgeschlossen. Die Vereinbarung umfasst die Entwicklung und Herstellung des Medikaments für klinische Phase II in Südkorea mit dem Ziel der Expansion nach Nordamerika. Dies stellt einen wichtigen Meilenstein für CPDC dar, da es seine Partnerschaften in der klinischen Entwicklung erweitern möchte.PR NewswireThe Centre for Probe Development and Commercialization expands into Asia and executes a development, manufacturing, and clinical supply agreement for 177Lu-PSMA (DGUL) With South Korea-based CellBionThe Centre for Probe Development and Commercialization (CPDC), a Canadian radiopharmaceutical CDMO, has signed a development, manufacturing, and clinical supply agreement with South Korea-based CellBion for Lu-177-PSMA (DGUL), a radiotherapeutic agent for prostate cancer currently in Phase II clinical trials in South Korea. Under the agreement, CPDC will develop and manufacture the drug product for clinical supply in South Korea with the goal of expanding into North America. This marks CPDC's strategic expansion into the Asian market, leveraging its expertise in GMP manufacturing and global distribution of radiotherapeutics.PR NewswireLe Centre for Probe Development and Commercialization prend de l'expansion en Asie et signe un accord de développement, de fabrication et d'approvisionnement clinique pour le 177Lu-PSMA (DGUL) avec CeThe Centre for Probe Development and Commercialization (CPDC) announced a development, manufacturing, and clinical supply agreement with CellBion for the Lu-177-PSMA (DGUL) radiotherapeutic agent targeting prostate cancer. Under the agreement, CPDC will develop and manufacture CellBion's pharmaceutical product for Phase II clinical supply in South Korea, with plans to expand to North America. The Lu-177-PSMA (DGUL) is currently in Phase II clinical trials in South Korea for metastatic castration-resistant prostate cancer, with CPDC leveraging its in-house n.c.a. Lu-177 production capability through its partnership with Isotopia Molecular Imaging.PR NewswireCPDC Announces Four New Appointments To Board of DirectorsThe Centre for Probe Development and Commercialization (CPDC) announced four new appointments to its Board of Directors effective June 17, 2021: Dr. Bettina Hamelin, Dr. Sheila Singh, Dr. Lana E. Janes, and Mr. Peter Pattison. The new directors bring expertise spanning genomics, cancer research, bioinnovation, and medical devices. CPDC also acknowledged three retiring board members, including Dr. Robert Sutherland who served as Board Chair for over 10 years.PR NewswireCPDC Announces Appointment of Bruno Paquin as Permanent CEOThe Centre for Probe Development and Commercialization (CPDC) appointed Bruno Paquin as its permanent Chief Executive Officer, effective March 4, 2021. This decision follows his successful tenure as interim CEO since joining the organization in 2018. CPDC continues to operate as a global leader in the discovery and commercialization of radiopharmaceuticals.PR NewswireCPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007The Centre for Probe Development and Commercialization (CPDC) announced that the first patient has been dosed in a Phase 3 clinical trial for [18F]PSMA-1007, a PET imaging agent targeting Prostate Specific Membrane Antigen (PSMA) for prostate cancer diagnosis. The trial will enroll 100 men with suspected persistent or recurrent prostate cancer at multiple Canadian clinical sites to evaluate the diagnostic performance and safety of the imaging agent. CPDC holds the exclusive license to develop, manufacture, and distribute [18F]PSMA-1007 in Canada, having licensed the product from ABX advanced biochemical compounds GmbH in Germany.PR NewswireCentre for Probe Development & Commercialization (CPDC) Appoints New Interim CEOThe Centre for Probe Development and Commercialization (CPDC) appointed Bruno Paquin as its new Interim CEO effective November 2, 2020. The organization, a global leader in radiopharmaceuticals, has expanded its capabilities and influence under its previous leadership, with plans to focus on strategic growth during the transition.PR NewswireCPDC Announces Appointment of Justyna Kelly as Permanent CEOThe Centre for Probe Development and Commercialization (CPDC) announced the appointment of Justyna Kelly as Permanent CEO, effective June 18, 2020, following her tenure as interim CEO since December 2019. Kelly has been with the organization for 10 years and previously led its microbiology and sterility assurance program, radiopharmaceutical development and manufacturing initiatives, and key internal programs. The company also appointed Dr. John Thornback as new Board Chair, who brings over 40 years of experience in the radiopharmaceutical and in vitro diagnostics industry.